Biomarker-adaptive clinical trial designs

Pharmacogenomics

Volumn 11, Issue 12, 2010, Pages 1679-1682

  Freidlin, Boris ^a   Korn, Edward L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

enrichment; interim monitoring; multi arm trials; randomized clinical trials; targeted therapy

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BREAST CANCER; CLINICAL RESEARCH; DIAGNOSTIC TEST; FACTORIAL DESIGN; HUMAN; MEDICAL CARE; METHODOLOGY; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PREDICTION; RANDOMIZATION; REVIEW; SAMPLE SIZE;

BIOMARKERS, PHARMACOLOGICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 78650334788     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.153     Document Type: Review

References (16)

1. Jennison C, Turnbull BW: Group Sequential Methods With Applications To Clinical Trials. Chapman & Hall/CRC, FL, USA (2000).
2. Freidlin B, Korn EL: Monitoring for lack of beneft: a critical component of a randomized clinical trial. J. Clin. Oncol. 27(4), 629-633 (2009).
3. Freidlin B, Korn EL, Gray R et al.: Multi-arm clinical trials of new agents: some design considerations. Clin. Cancer Res. 14(14), 4368-4371 (2008).
4. Hunsberger S, Zhao Y, Simon R: A comparison of Phase II study strategies. Clin. Cancer Res. 15(19), 5950-5955 (2009).
5. Bauer P: Adaptive designs: looking for a needle in the haystack - a new challenge in medical research. Stat. Med. 27(10), 1565-1580 (2008).
6. Tsiatis AA, Mehta C: On the ineffciency of the adaptive design for monitoring clinical trials. Biometrika 90(2), 367-378 (2003).
7. Korn EL, Freidlin B: Outcome-adaptive randomization: is it useful? J. Clin. Oncol. doi: 10.1200/JCO.2010.31.1423 (2010) (In Press).
8. Simon R, Maitournam A: Evaluating the effciency of targeted designs for randomized clinical trials. Clin. Cancer Res. 10(20), 6759-6763 (2004).
9. Mandrekar SJ, Sargent DJ: Predictive biomarker validation in practice: lessons from real trials. Clin. Trials 7(5), 567-573 (2010).
10. Liu A, Liu C, Yu KF et al.: A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations. Clin. Trials 7(5), 537-545 (2010).
11. Simon R: Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per. Med. 7(1), 33-47 (2010).
12. Barker AD, Sigman CC, Kelloff GJ et al.: I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86(1), 97-100 (2009).
13. Freidlin B, McShane LM, Korn EL: Randomized clinical trials with biomarkers: design issues. J. Natl. Cancer Inst. 102(3), 152-160 (2010).
14. Jiang W, Freidlin B, Simon R: Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defned subset effect. J. Natl. Cancer Inst. 99 (13), 1036-1043 (2007).
15. Freidlin B, Simon R: Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin. Cancer Res.11(21), 7872-7878 (2005).
16. Freidlin B, Jiang W, Simon R: The cross-validated adaptive signature design. Clin. Cancer Res. 16(2), 691-698 (2010).